Optimi Health completes commercial psilocybin production for Australian market
OPTH sits 95% above its 52-week low of $3.
Summary
Optimi Health has completed a GMP production run of 5mg psilocybin capsules, which are now commercially prescribed for treatment-resistant depression in Australia. This significant operational milestone follows Australia's recent regulatory changes expanding access to psychedelics and was also disclosed in a 6-K today. The company's vertical integration and Health Canada license enable it to supply this emerging market. Additional product from this run is earmarked for planned clinical trials in the United States and Europe, indicating potential for future market expansion.
At the time of this announcement, OPTH was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $3.00 to $8.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.